Clinical trial · Observational
Immunotherapy in Lymphoma
Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed/refractory high grade B cell lymophoma patients. The main question it aims to answer is: Does advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies? Researchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes. Laboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Burkitt Lymphoma | Burkitt Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Diffuse Large B Cell Lymphoma Relapsed | — | UNRESOLVED | — |
| High Grade B-cell Lymphoma | High Grade B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Primary Mediastinal Large B-Cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Relapsed/refractory High Grade B Cell Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Antibody-Drug Conjugate | Drug | — | UNRESOLVED |
| Bispecific antibody | Drug | — | UNRESOLVED |
| CAR-T Therapy | Drug | — | UNRESOLVED |
| IMiD treatment | Drug | — | UNRESOLVED |
| Monoclonal antibody | Drug | — | UNRESOLVED |
| Proteasome Inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Advanced immunochemotherapy
- description
- Relapsed/refractory high grade B cell lymphoma patients treated with either chimeric antigen receptor T cell therapy, bispecific antibody, or antibody-drug conjugate
- interventionNames
- Drug: CAR-T Therapy
- Drug: Bispecific antibody
- Drug: Antibody-Drug Conjugate
- label
- Classical Immunochemotherapy
- description
- Relapsed/refractory high grade B cell lymphoma patients treated with either proteasome inhibitor, immune modulatory drug, or monoclonal antibody.
- interventionNames
- Drug: Monoclonal antibody
- Drug: Proteasome Inhibitor
- Drug: IMiD treatment
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * Adults aged 19 to 74 years. * Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma * Patients who have received immunochemotherapy as treatment for relapsed/refractory lymphoma Exclusion Criteria: * Patients who have progressed to acute leukemia * Patients who developed solid tumor during treatment * Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.)
References
Publications (0)
Data not yet available